Silverman, Daniel, M.D., Ph.D.
  • Clinical Professor, Biomedical Physics IDP and Molecular & Medical Pharmacology at UCLA

  • Member, ACCESS Program: Dept. of Molecular & Medical Pharmacology

Silverman, Daniel, M.D., Ph.D.

Contact

Medical Center, MC694215
Los Angeles, CA 90095
Tel: (310) 825-4257
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Specialty

Neuronuclear Imaging, Biochemistry, Molecular and Medical Pharmacology.

Top

Biography

Daniel H. Silverman, M.D., Ph.D., is Head of the Neuronuclear Imaging Section of the Ahmanson Translational Imaging Division at UCLA Medical Center, on the Executive Committee of the UCLA Alzheimer's Disease Research Center, and a Professor in the Department of Molecular and Medical Pharmacology, University of California, Los Angeles. He obtained his Ph.D. in Biological Chemistry at Harvard University, and postdoctoral research training in Biochemistry and Molecular Pharmacology at Harvard Medical School. He obtained his M.D. from The Ohio State University College of Medicine, subsequently completed post-M.D. training at UCLA, and then obtained certification from both the American Board of Internal Medicine and the American Board of Nuclear Medicine.

Top

Publications (selected peer-reviewed publications)

  • Ercoli LM, Small GW, Siddarth P, Kepe V, Huang, SC, Miller KJ, Lavretsky H, Bookheimer SY, Barrio JR, Silverman DHS. Assessment of dementia risk in aging adults using both FDG-PET and FDDNP-PET imaging, Int J Geriatr Psychiatry. 2012;27(10):1017-1027. doi: 10.1002/gps.2816. PMID: 22383132
  • Seibyl JP, Chen W, and Silverman DHS. 3,4-Dihydroxy-6- [F-18] -Fluoro-L-Phenylalanine Positron Emission Tomography in Patients with Central Motor Disorders and in Evaluation of Brain and Other Tumors. Seminars in Nuclear Medicine 2007;37:440-450.
  • Silverman DHS, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, Waddell K, Petersen L, Phelps ME, Ganz PA Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5 to 10 years after chemotherapy. Breast Cancer Res Treat 2007;103:303-311.
  • Kesner AL, Hsueh W-A, Htet NL, Pio BS, Czernin J, Pegram MD, Phelps ME, Silverman DHS. Biodistribution and predictive value of 18F-fluorocyclophosphamide in mice bearing human breast xenografts. J Nucl Med 2007;48:2021-2027.
  • Chen W, Delaloye S, Silverman DHS, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation with 18F-FLT PET. J Clin Oncol 2007;25:4714-4721.
  • Silverman DHS and Thompson PM. Structural and functional neuroimaging: focusing on mild cognitive impairment. Appl Neurol 2006;2:10-22.
  • Chen W, Silverman DHS, DelaloyeS, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T. 18F-FDOPA PET Imaging of Brain Tumors: Comparison Study with 18F-FDG PET and Evaluation of Diagnostic Accuracy. J Nucl Med 2006;47:904-911.
  • Top